Reid Hoffman exits Microsoft’s board after a decade of influence, citing a return to “founder mode.” The former LinkedIn CEO joined the board post‑acquisition in 2016 and helped steer Microsoft’s $1 billion OpenAI investment and a $650 million Inflection AI deal. His tenure saw Microsoft deepen its AI strategy, while he maintained ties to emerging startups continually.

Hoffman’s move follows his recent podcast chat with Satya Nadella, where he expressed a desire to focus on Manus, an AI‑driven drug‑discovery venture that raised over $50 million last year. Manus, co‑founded by Hoffman, aims to accelerate cancer research through “Move 37” AI that surpasses human chemistry design for potential therapeutics and patient care worldwide in 2026.

Microsoft gains a free board seat to allocate capital elsewhere, while Hoffman steps into a leadership role as chairman rather than CEO. Manus’ chief executive, Dr. Siddhartha Mukherjee, brings scientific gravitas, but Hoffman’s business acumen will guide fundraising and strategic partnerships, potentially reshaping the AI‑driven pharma landscape for global drug development efforts in the sector.

With Hoffman’s departure, Microsoft sidesteps potential conflicts over its AI investments, while Manus gains a seasoned strategist to navigate regulatory hurdles and investor scrutiny. The move underscores the growing trend of high‑profile tech leaders pivoting to niche AI initiatives that promise high impact and commercial upside for investors and stakeholders in 2026 markets globally today.